NDA 017874 · Baxter Hlthcare Corp
Transderm Scop
Scopolamine · Transdermal · Anticholinergic
Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Dec 31, 1979
Approved uses
2
Original approval plus efficacy supplements
Registered trials
387
119 Phase 3, 9 recruiting
FAERS reports
5,759
3,941 serious, 765 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 10, 2025.
TRANSDERM SCŌP is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )
Mechanism: Scopolamine, a belladonna alkaloid, is an anticholinergic. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2019 Supplement 43 · Efficacy LabelLetter
- Dec 31, 1979 Original approval · Type 3 - New Dosage Form
1 products under this application
- TRANSDERM SCOP · SCOPOLAMINE 1MG/72HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Scopolamine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01126437 · 17,183 participants · Start May 2010 · Primary completion May 2013
Drug: tiotropium 18 mcg; tiotropium 1.25 mcg (2 actuations/day) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 1,191 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02296138 · 7,903 participants · Start Jan 13, 2015 · Primary completion Mar 8, 2017
Drug: olodaterol; tiotropium and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Birmingham, Alabama; Florence, Alabama · 818 sites in all
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00144339 · 5,993 participants · Start Dec 2002 · Primary completion Feb 2008
Drug: tiotropium; placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Anniston, Alabama; Birmingham, Alabama; Jasper, Alabama · 490 sites in all
- Tiotropium / Respimat One Year Study in COPD.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00387088 · 3,991 participants · Start Sep 2006 · Primary completion Jan 2009
Drug: Tiotropium · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Mobile, Alabama; Berkeley, California · 334 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
- Exacerbation StudyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00845728 · 3,439 participants · Start Mar 2009 · Primary completion Jul 2012
Drug: Indacaterol 150 µg; Tiotropium · For: Chronic Obstructive Pulmonary Disease
Sites: Buenos Aires, Argentina; Capital Federal, Argentina; Mar del Plata, Argentina · 423 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea711
- off label use609
- vomiting501
- dizziness454
- headache366
- drug ineffective346
- fatigue300
- vision blurred279
- death257
- diarrhoea252
- malaise252
- confusional state243
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 48 |
| 2006 | 60 |
| 2007 | 51 |
| 2008 | 92 |
| 2009 | 85 |
| 2010 | 118 |
| 2011 | 262 |
| 2012 | 248 |
| 2013 | 135 |
| 2014 | 143 |
| 2015 | 169 |
| 2016 | 539 |
| 2017 | 408 |
| 2018 | 370 |
| 2019 | 356 |
| 2020 | 221 |
| 2021 | 309 |
| 2022 | 510 |
| 2023 | 483 |
| 2024 | 403 |
| 2025 | 394 |
| 2026 | 322 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Transderm-Scop (Scopolamine)
2024 spending
$291K
Beneficiaries
768
1,636 claims
Per beneficiary
$378
$19.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,262,354 |
| 2021 | $1,002,465 |
| 2022 | $443,626 |
| 2023 | $347,632 |
| 2024 | $290,661 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis.
Weibel S, Schaefer MS, Raj D, et al. · Anaesthesia 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Involvement of muscarinic acetylcholine receptor-mediated cholinergic neurotransmission in TMS-EEG responses.
Song Y, Gordon PC, Roy O, et al. · Prog Neuropsychopharmacol Biol Psychiatry 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Scopolamine for patients with motion sickness: a systematic review and meta-analysis with trial sequential analysis.
Zhang YX, Niu XY, Xiao ZY, et al. · Acta Otolaryngol 2024 · Systematic Review, Meta-Analysis
- Estradiol treatment in young postmenopausal women with self-reported cognitive complaints: Effects on cholinergic-mediated cognitive performance.
Conley AC, Albert KM, McDonald BC, et al. · Hum Psychopharmacol 2022 · Controlled Clinical Trial, Research Support, N.I.H., Extramural
- Two decades of research towards a potential first anti-epileptic drug.
Benassi SK, Alves JGSM, Guidoreni CG, et al. · Seizure 2021 · Randomized Controlled Trial
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.